Cel Sci (CVM) Net Income (2010 - 2026)
Cel Sci (CVM) posted Net Income of -$13.0 million for Q1 2026, down 134.11% sequentially from -$5.5 million in Q4 2025, and down 97.11% YoY from -$447.6 million in Q1 2025.
Cel Sci (CVM) Net Income (2010 - 2026) Analysis & Trends
Cel Sci has reported Net Income for 17 years, with the latest figure at -$13.0 million in Q1 2026.
- Quarterly Net Income fell 97.11% year-over-year to -$13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.6 million (down 6.86% YoY) and the FY2025 annual result came in at -$90.7 million, down 2.09% from the prior year.
- Net Income retreated to -$13.0 million in Q1 2026 per CVM's latest filing, from -$5.5 million in the prior quarter.
- Over five years, Net Income peaked at -$5.5 million in Q4 2025 and troughed at -$27.8 million in Q1 2022.
- A 5-year average of -$14.6 million and a median of -$13.0 million in 2026 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2025: Net Income plunged 154.62% in 2023, then surged 67.46% in 2025.
- Over 5 years, Net Income stood at -$8.0 million in 2022, then plunged by 154.62% to -$20.2 million in 2023, then soared by 64.92% to -$7.1 million in 2024, then climbed by 22.08% to -$5.5 million in 2025, then sank by 134.11% to -$13.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$13.0 million, -$5.5 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.95 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -15.22 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -6.16 Mn |
| Jun 30, 2024 | -19.13 Mn |
| Mar 31, 2024 | -20.20 Mn |
| Dec 31, 2023 | -20.24 Mn |
| Sep 30, 2023 | -8.08 Mn |
| Jun 30, 2023 | -23.25 Mn |
| Mar 31, 2023 | -23.89 Mn |
| Dec 31, 2022 | -7.95 Mn |
| Sep 30, 2022 | -10.48 Mn |
| Jun 30, 2022 | -26.34 Mn |
| Mar 31, 2022 | -27.76 Mn |
| Dec 31, 2021 | -9.13 Mn |
| Sep 30, 2021 | -8.60 Mn |
| Jun 30, 2021 | -10.48 Mn |